Results 251 to 260 of about 55,011 (304)

The Impact of Glucagon-like Peptide-1 Receptor Agonists on Obese Individuals’ Quality of Life and Eating Behaviors

Aya Saad Aldewachi, Mohammed Aladul
openalex   +1 more source

Adenoma and Sessile Serrated Polyp Detection Rates in Adults Using Glucagon-Like Peptide-1 Receptor Agonists. [PDF]

Clin Transl Gastroenterol
Garg S, Hoxha D, Long D, Valencia S, Yang Q, Lembo A, Vargo JJ, Chiang DJ.   +7 more
europepmc   +1 more source

Angiotensin‐converting enzyme and exercise adaptations: Genetic variability, pharmacological modulation and future directions

The Journal of Physiology, EarlyView.
Abstract figure legend ACE I/D genotype, enzyme activity and integrated physiological adaptations. Upper panel: Conceptual framework linking the ACE I/D polymorphism (left) with circulating/tissue ACE activity (centre; violin plots based on hypothetical data for illustration) and strength/power versus endurance phenotypes (right).
Tórur Sjúrðarson, Nikolai B. Nordsborg   +1 more
wiley   +1 more source

Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: a population study in Great Britain. [PDF]

BMC Med
Jackson SE, Brown J, Llewellyn C, Mytton O, Shahab L.   +4 more
europepmc   +1 more source

Deciphering pro‐arrhythmogenic mechanisms of EPAC in human atrial cardiomyocytes

The Journal of Physiology, EarlyView.
Abstract figure legend This study aimed to investigate the effect of exchange proteins directly activated by cAMP (EPAC) on the regulation of human atrial cardiomyocyte electrophysiology and their potential involvement in the onset of atrial fibrillation (AF).
Arthur Boileve, Margaux Aize, Maximin Détrait, Laura Brard, Adrien Leboyer, Pierre‐Antoine Dupont, Alexandre Lebrun, Vladimir Saplacan, Christophe Simard, Fabien Brette, Frank Lezoualc'h, Laurent Sallé   +11 more
wiley   +1 more source

Impact of Glucagon-Like Peptide-1 Receptor Agonists on Hip Arthroplasty Outcomes: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Zaffar H, Imran MA, Hussain S, Rushd F.
europepmc   +1 more source

Semaglutide impacts skeletal muscle to a similar extent as caloric restriction in mice with diet‐induced obesity

The Journal of Physiology, EarlyView.
Abstract figure legend Four weeks of semaglutide treatment causes significant reductions in total body weight, fat mass, lean mass, and grip strength in mice with diet induced obesity. Mice treated with semaglutide lost a greater amount of total body weight and fat mass compared to mice fed fed a calorie matched diet.
S. Jeromson, B. Baranowski, M. Akcan, B. D. Waters, K. Eisner, A. Bellucci, S. Trang, A. Abolhassani, M. A. Tello‐Palencia, A. Schweitzer, B. Stefanska, C. J. Mitchell, David C. Wright   +12 more
wiley   +1 more source

Assessing the Oncological Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Jaradat JH, Al-Ahmad RI, Al Jaghbeer M, Abdelaziz AA, Abu Afifeh NM, Abu Afifeh G, Rao A, Alzoubi A, Nashwan AJ.   +8 more
europepmc   +1 more source

The Cardiovascular Physiology of Glucagon-like Peptide-1 Receptor Agonists: From Macro-level Outcomes to Micro-level Mechanisms

Masab Mansoor
openalex   +2 more sources

Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide 1 Receptor Agonists, and Frailty Progression in Older Adults With Type 2 Diabetes. [PDF]

Diabetes Care
Park CM, Thanapluetiwong S, Chen X, Oh G, Ko D, Kim DH.   +5 more
europepmc   +1 more source